Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma's stock has been impacted by several events. Q3 2025 earnings missed expectations, while Q1 2025 showed promising Phase 1a data for NXP900 and secured $15.5 million in financing. Disappointing Phase 1b results for NXP800 led to a stock drop, but the company is exploring higher dosing. A $15.5 million public offering was completed in February 2025, extending the cash runway into 2027. Insider buying occurred in November 2025 and February 2025. As of November 28, 2025, the stock has increased by 13.9% since the start of the year.

As a clinical-stage biopharmaceutical company, Nuvectis Pharma, Inc. does not experience traditional demand seasonality. Demand for its investigational oncology treatments is driven by ongoing medical needs and the advancement of its pipeline, which is not subject to seasonal fluctuations.

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for oncology. Their pipeline includes NXP800, a small molecule in Phase 1b clinical trial for platinum-resistant ARID1a-mutated ovarian carcinoma, with potential for other cancers and Orphan Drug Designation. NXP900, another small molecule in Phase 1a clinical trial, inhibits c-Src and YES1 kinases for solid tumors, with a Phase 1b program initiated and a combination arm expected by year-end 2025.

Nuvectis Pharma, Inc. is headquartered in Fort Lee, New Jersey, United States. Its primary operations and clinical trials are based in the U.S., with potential future expansion beyond the U.S. market.

Nuvectis Pharma has generally maintained a positive brand reputation, with a "Strong Buy" consensus rating from analysts as of November 25, 2025. Positive Phase 1a data for NXP900 and Orphan Drug Designation for NXP800 have enhanced its reputation. Hosting Key Opinion Leader meetings also demonstrates transparency. However, disappointing Phase 1b results for NXP800 in November 2024 negatively impacted its reputation, but the company's proactive approach helps mitigate the impact.

Nuvectis Pharma, Inc. has a diverse ownership structure with approximately 14.42% held by institutional shareholders, 41.62% by insiders, and 43.96% by retail investors. Major institutional owners include Vanguard Group Inc. and BlackRock, Inc. Ron Bentsur, the Chairman and CEO, is the largest individual shareholder.